NO301713B1 - Krystallinske oksatiolan-derivater - Google Patents
Krystallinske oksatiolan-derivater Download PDFInfo
- Publication number
- NO301713B1 NO301713B1 NO922182A NO922182A NO301713B1 NO 301713 B1 NO301713 B1 NO 301713B1 NO 922182 A NO922182 A NO 922182A NO 922182 A NO922182 A NO 922182A NO 301713 B1 NO301713 B1 NO 301713B1
- Authority
- NO
- Norway
- Prior art keywords
- crystalline form
- cis
- oxathiolan
- pyrimidin
- amino
- Prior art date
Links
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical class C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical group O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 238000002329 infrared spectrum Methods 0.000 claims description 12
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000011928 denatured alcohol Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 238000010533 azeotropic distillation Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- SMKDHPIQHWRJFP-UHFFFAOYSA-N (5-methoxy-1,3-oxathiolan-2-yl)methyl benzoate Chemical compound O1C(OC)CSC1COC(=O)C1=CC=CC=C1 SMKDHPIQHWRJFP-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102100026846 Cytidine deaminase Human genes 0.000 description 2
- 108010031325 Cytidine deaminase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
- OQEDEGGYERFFGP-UHFFFAOYSA-N 2-oxoethyl benzoate Chemical compound O=CCOC(=O)C1=CC=CC=C1 OQEDEGGYERFFGP-UHFFFAOYSA-N 0.000 description 1
- FLJWVVUJGVNXMZ-UHFFFAOYSA-N 2-sulfanylacetaldehyde Chemical compound SCC=O FLJWVVUJGVNXMZ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- QYKULYCDZYBCJJ-QWHCGFSZSA-N [(2r,5s)-5-(2,4-dioxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound N1([C@H]2O[C@H](SC2)COC(=O)C=2C=CC=CC=2)C=CC(=O)NC1=O QYKULYCDZYBCJJ-QWHCGFSZSA-N 0.000 description 1
- SWOOIHFMFZUHOC-QWHCGFSZSA-N [(2r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methyl benzoate Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](COC(=O)C=2C=CC=CC=2)SC1 SWOOIHFMFZUHOC-QWHCGFSZSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Secondary Cells (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919111902A GB9111902D0 (en) | 1991-06-03 | 1991-06-03 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922182D0 NO922182D0 (no) | 1992-06-02 |
| NO922182L NO922182L (no) | 1992-12-04 |
| NO301713B1 true NO301713B1 (no) | 1997-12-01 |
Family
ID=10696001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922182A NO301713B1 (no) | 1991-06-03 | 1992-06-02 | Krystallinske oksatiolan-derivater |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5905082A (xx) |
| EP (2) | EP1099700A1 (xx) |
| JP (1) | JP2851480B2 (xx) |
| KR (1) | KR100244008B1 (xx) |
| AP (1) | AP300A (xx) |
| AT (1) | ATE212630T1 (xx) |
| AU (2) | AU656379B2 (xx) |
| BG (1) | BG60914B1 (xx) |
| CA (2) | CA2311988C (xx) |
| CZ (1) | CZ284513B6 (xx) |
| DE (1) | DE69232387T2 (xx) |
| DK (1) | DK0517145T3 (xx) |
| ES (1) | ES2171158T3 (xx) |
| GB (1) | GB9111902D0 (xx) |
| GE (1) | GEP19991834B (xx) |
| HK (1) | HK1009599A1 (xx) |
| IE (2) | IE921780A1 (xx) |
| IL (1) | IL102073A (xx) |
| IS (2) | IS1867B (xx) |
| MX (1) | MX9202619A (xx) |
| NO (1) | NO301713B1 (xx) |
| NZ (1) | NZ242981A (xx) |
| OA (1) | OA09913A (xx) |
| PT (1) | PT517145E (xx) |
| RU (1) | RU2102393C1 (xx) |
| SG (1) | SG52455A1 (xx) |
| SK (1) | SK281249B6 (xx) |
| TW (1) | TW254939B (xx) |
| UA (1) | UA41265C2 (xx) |
| WO (1) | WO1992021676A1 (xx) |
| ZA (1) | ZA924007B (xx) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4581979A (en) * | 1983-07-01 | 1986-04-15 | Automotive Products Plc | Shipping and installation restraining clip for master cylinder input member |
| US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
| US5914331A (en) * | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5827727A (en) * | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6812233B1 (en) | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
| US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
| GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
| US6177435B1 (en) | 1992-05-13 | 2001-01-23 | Glaxo Wellcome Inc. | Therapeutic combinations |
| US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| US5587362A (en) * | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| US6391859B1 (en) | 1995-01-27 | 2002-05-21 | Emory University | [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides |
| US5703058A (en) * | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| US5808040A (en) * | 1995-01-30 | 1998-09-15 | Yale University | L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides |
| DE69636734T2 (de) | 1995-06-07 | 2007-10-18 | Emory University | Nucleoside mit anti-hepatitis b virus wirksamkeit |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| PL330747A1 (en) | 1996-06-25 | 1999-05-24 | Glaxo Group Ltd | Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections |
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
| US6436948B1 (en) | 2000-03-03 | 2002-08-20 | University Of Georgia Research Foundation Inc. | Method for the treatment of psoriasis and genital warts |
| CN1503796B (zh) | 2001-03-01 | 2012-07-04 | 三角药品公司 | 顺-ftc的多晶型物及其它晶型 |
| CA2351049C (en) | 2001-06-18 | 2007-03-13 | Brantford Chemicals Inc. | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers |
| WO2003027106A1 (en) * | 2001-09-25 | 2003-04-03 | Cadila Healthcar Limited | Process for the preparation of crystalline polymorph ii of lamivudine |
| AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
| US20050287177A1 (en) * | 2002-11-08 | 2005-12-29 | Glaxo Group Unlimited And Smithkline Beecham Corp. | Pharmaceutical compositions |
| WO2004064846A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| PL1809662T3 (pl) * | 2004-11-10 | 2009-07-31 | Novartis Vaccines & Diagnostics Inc | Dezamidowany interferon-beta |
| US20060242012A1 (en) * | 2005-04-22 | 2006-10-26 | Sumit Agarwal | Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| JP5184511B2 (ja) * | 2006-04-18 | 2013-04-17 | ルピン・リミテッド | 新しい結晶形態のラミブジン |
| US20090068267A1 (en) * | 2007-09-06 | 2009-03-12 | Combino Pharm, S.L. | Novel Pharmaceutical Compositions |
| US20100190982A1 (en) * | 2007-09-17 | 2010-07-29 | Janardhana Rao Vascuri | Process for the preparation of lamivudine form i |
| SI2225232T1 (sl) * | 2007-11-29 | 2012-12-31 | Ranbaxy Laboratories Limited | Postopek za pripravo substituiranih 1,3-oksatiolanov |
| AU2008331167A1 (en) * | 2007-11-29 | 2009-06-04 | Ranbaxy Laboratories Limited | Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine |
| BRPI0820222A2 (pt) * | 2007-11-29 | 2015-06-16 | Ranbaxy Lab Ltd | Forma i cristalina estável de lamivudina e processo de preparação |
| WO2009127996A1 (en) * | 2008-04-17 | 2009-10-22 | Ranbaxy Laboratories Limited | Novel crystalline form of lamivudine |
| US8536151B2 (en) * | 2008-09-01 | 2013-09-17 | Hetero Research Foundation | Process for preparing lamivudine polymorph form |
| EP2350065A1 (en) * | 2008-11-12 | 2011-08-03 | Lupin Ltd. | A novel polymorph of emtricitabine and a process for preparing of the same |
| CN101531656B (zh) * | 2009-03-24 | 2010-12-08 | 福建广生堂药业有限公司 | 拉米夫定晶型及其制备方法 |
| CN101993439B (zh) * | 2009-03-24 | 2013-04-24 | 福建广生堂药业股份有限公司 | 拉米夫定晶型及其制备方法 |
| WO2010137027A1 (en) * | 2009-05-27 | 2010-12-02 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
| EP2454244B1 (en) | 2009-07-15 | 2013-06-26 | Lupin Limited | An improved process for preparation of efavirenz |
| WO2011045815A2 (en) | 2009-10-14 | 2011-04-21 | Matrix Laboratories Ltd. | Process for the preparation of lamivudine and novel salts in the manufacture thereof |
| US20120295898A1 (en) | 2010-01-27 | 2012-11-22 | Mark Richard Underwood | Antiviral Therapy |
| US20120295930A1 (en) * | 2010-02-03 | 2012-11-22 | Shankar Rama | Novel process for the preparation of cis-nucleoside derivative |
| US8796452B2 (en) * | 2010-02-12 | 2014-08-05 | Merck Sharp & Dohme Corp. | Preparation of lamivudine form I |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| WO2013021290A1 (en) | 2011-08-05 | 2013-02-14 | Lupin Limited | A stereoselective process for preparation of 1,3-oxathiolane nucleosides |
| WO2013168066A1 (en) | 2012-05-05 | 2013-11-14 | Lupin Limited | An improved process for the manufacture of lamivudine form i. |
| CN114099454B (zh) * | 2020-08-31 | 2023-06-27 | 长春海悦药业股份有限公司 | 一种拉米夫定片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
| US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
-
1991
- 1991-06-03 GB GB919111902A patent/GB9111902D0/en active Pending
-
1992
- 1992-02-06 UA UA93004068A patent/UA41265C2/uk unknown
- 1992-06-02 ZA ZA924007A patent/ZA924007B/xx unknown
- 1992-06-02 TW TW081104300A patent/TW254939B/zh not_active IP Right Cessation
- 1992-06-02 US US07/892,029 patent/US5905082A/en not_active Expired - Lifetime
- 1992-06-02 CZ CS932612A patent/CZ284513B6/cs not_active IP Right Cessation
- 1992-06-02 MX MX9202619A patent/MX9202619A/es active IP Right Grant
- 1992-06-02 EP EP01200491A patent/EP1099700A1/en not_active Withdrawn
- 1992-06-02 NO NO922182A patent/NO301713B1/no not_active IP Right Cessation
- 1992-06-02 AU AU17361/92A patent/AU656379B2/en not_active Expired
- 1992-06-02 IS IS3873A patent/IS1867B/is unknown
- 1992-06-02 DK DK92109221T patent/DK0517145T3/da active
- 1992-06-02 AT AT92109221T patent/ATE212630T1/de active
- 1992-06-02 AU AU18810/92A patent/AU1881092A/en not_active Abandoned
- 1992-06-02 NZ NZ242981A patent/NZ242981A/en not_active IP Right Cessation
- 1992-06-02 SK SK1257-93A patent/SK281249B6/sk not_active IP Right Cessation
- 1992-06-02 EP EP92109221A patent/EP0517145B1/en not_active Expired - Lifetime
- 1992-06-02 SG SG1996004763A patent/SG52455A1/en unknown
- 1992-06-02 AP APAP/P/1992/000395A patent/AP300A/en active
- 1992-06-02 CA CA002311988A patent/CA2311988C/en not_active Expired - Lifetime
- 1992-06-02 GE GEAP19922654A patent/GEP19991834B/en unknown
- 1992-06-02 RU RU93058495A patent/RU2102393C1/ru active
- 1992-06-02 ES ES92109221T patent/ES2171158T3/es not_active Expired - Lifetime
- 1992-06-02 WO PCT/EP1992/001213 patent/WO1992021676A1/en active IP Right Grant
- 1992-06-02 KR KR1019920009537A patent/KR100244008B1/ko not_active IP Right Cessation
- 1992-06-02 CA CA002070230A patent/CA2070230C/en not_active Expired - Lifetime
- 1992-06-02 PT PT92109221T patent/PT517145E/pt unknown
- 1992-06-02 DE DE69232387T patent/DE69232387T2/de not_active Expired - Lifetime
- 1992-06-02 IL IL10207392A patent/IL102073A/en not_active IP Right Cessation
- 1992-06-02 JP JP4166809A patent/JP2851480B2/ja not_active Expired - Lifetime
- 1992-07-01 IE IE178092A patent/IE921780A1/en not_active IP Right Cessation
- 1992-07-01 IE IE20020782A patent/IE20020782A1/en not_active IP Right Cessation
- 1992-12-04 IS IS4268A patent/IS4268A/is unknown
-
1993
- 1993-11-15 OA OA60437A patent/OA09913A/en unknown
- 1993-11-30 BG BG98254A patent/BG60914B1/bg unknown
-
1998
- 1998-08-31 HK HK98110312A patent/HK1009599A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO301713B1 (no) | Krystallinske oksatiolan-derivater | |
| IE83503B1 (en) | Crystalline oxathiolane derivatives | |
| NO180377B (no) | Analogifremgangsmåte ved fremstilling av aktive 1,3-oksatiolannukleosidanaloger | |
| AU2012327780B2 (en) | Kinase inhibitor and method for treatment of related diseases | |
| IL259150A (en) | Derivative of pyrimidine and its use | |
| NO332306B1 (no) | Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning | |
| NO333586B1 (no) | Krystallinsk clopidogrel og fremgangsmate for fremstilling derav | |
| WO2013038425A1 (en) | Rilpivirine hydrochloride | |
| JP6980779B2 (ja) | 肝臓送達に基づく抗ウイルス性プロドラッグであるヌクレオシド環状リン酸エステル化合物およびその使用 | |
| EP2646431B1 (en) | A process for the preparation of pazopanib using novel intermediate | |
| AU2015342444A1 (en) | Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof | |
| AU2008331168A1 (en) | Crystalline form I of lamivudine and its preparation | |
| MXPA03002088A (es) | Compuestos derivados de quinazolina, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a los mismos. | |
| JPS6317884A (ja) | トリシクロ化合物 | |
| Bambury et al. | Mesoionic pyridazine ribonucleosides. A novel biologically active nucleoside metabolite | |
| CN109843300A (zh) | 3-羟基-4,5-双苄氧基-6-苄氧基甲基-2-苯基-2-氧代-2λ5-[1,2]氧杂膦环己烷的结晶多晶型形式 | |
| US20060094764A1 (en) | Cyanothiophenes, their preparation and their use in pharmaceutical compositions | |
| WO2024037422A1 (en) | Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof | |
| JP2006232671A (ja) | 新規セレナゾリン誘導体 | |
| EP4089095A1 (en) | Deuterated thienopyridine compound | |
| HU220760B1 (hu) | A-2-receptor affinitású R-2-[(fenil-izopropil)-amino]-adenozin, előállítása, alkalmazása és azt tartalmazó gyógyszerkészítmény | |
| NO172582B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive estere og amider av nukleosid-derivater | |
| MXPA96004670A (en) | Procedure for the preparation of compounds of imidazolyl enantiomerically pu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |